Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
Public ClinicalTrials.gov record NCT05853367. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors.
Study identification
- NCT ID
- NCT05853367
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 178 participants
Conditions and interventions
Conditions
Interventions
- MK-0472 Drug
- MK-1084 Drug
- Pembrolizumab Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 5, 2023
- Primary completion
- Feb 11, 2028
- Completion
- Feb 11, 2028
- Last update posted
- Mar 12, 2026
2023 – 2028
United States locations
- U.S. sites
- 4
- U.S. states
- 3
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Northwestern Memorial Hospital ( Site 0002) | Chicago | Illinois | 60611 | Recruiting |
| The University of Louisville, James Graham Brown Cancer Center ( Site 0004) | Louisville | Kentucky | 40202 | Recruiting |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 0001) | Hackensack | New Jersey | 07601 | Recruiting |
| Rutgers Cancer Institute of New Jersey ( Site 0005) | New Brunswick | New Jersey | 08901 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05853367, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 12, 2026 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05853367 live on ClinicalTrials.gov.